8-K: iSpecimen Secures $5.5M in Private Preferred Stock Offering

iSpecimen Inc. has raised $5.5 million through a private placement of Series C Convertible Non-Voting Preferred Stock to accredited investors.

Summary

• iSpecimen Inc. entered into a Securities Purchase Agreement on December 30, 2025, to sell 6,875 shares of newly-designated Series C Convertible Non-Voting Preferred Stock.
• The Series C Preferred Stock has a stated value of $1,000 per share but was sold at a purchase price of $800 per share, resulting in aggregate gross proceeds of $5.5 million.
• Each share of Series C Preferred Stock is convertible into common stock at a conversion price equal to 85% of the common stock's closing price on the trading day preceding conversion, with a floor price of $0.0681.
• The company also entered into a Registration Rights Agreement, committing to register the common stock issuable upon conversion for resale.
• E.F. Hutton & Co. served as the exclusive placement agent, receiving a 4.0% cash fee and a 1.0% non-accountable expense allowance based on the gross proceeds.
• The net proceeds from the offering are intended for marketing and working capital purposes.
• The Series C Preferred Stock ranks senior to common stock regarding dividends, distributions, and liquidation payments, but has no voting rights except for specific adverse changes to its terms.
• A mandatory reverse stock split mechanism is in place if the common stock's lowest closing price falls below the Floor Price ($0.0681) for five consecutive trading days, with potential liquidated damages for non-compliance.

Sentiment

Score: 3

Explanation: While the capital raise provides necessary funding, the terms of the private placement (significant discount, low conversion floor price, and substantial liquidated damages for non-compliance) indicate a challenging financial position and potential for significant dilution and operational hurdles for common shareholders. The mandatory reverse stock split provision further underscores these concerns.

Positives

• The company successfully raised $5.5 million in capital, providing funds for marketing and working capital.
• The Series C Preferred Stock ranks senior to common stock in terms of dividends, distributions, and liquidation, offering a level of security to the new investors.
• The preferred stock is non-voting, preventing immediate dilution of voting control for existing common shareholders.

Negatives

• The Series C Preferred Stock was sold at a 20% discount to its stated value ($800 purchase price for $1,000 stated value), indicating less favorable terms for the company.
• The conversion price for the Series C Preferred Stock is set at 85% of the common stock's closing price, with a low floor price of $0.0681, which could lead to significant dilution for existing common shareholders.
• The company faces substantial liquidated damages (e.g., 120% of shares not issued for conversion failure, 1.0% of stated value for public information failure, 20.0% of purchase price for reverse split failure) if it fails to meet various obligations, highlighting potential operational and compliance risks.
• High placement agent fees totaling 5% of gross proceeds ($275,000) reduce the net capital raised.

Risks

• Significant dilution of common stock upon conversion of the Series C Preferred Stock, especially given the 85% conversion discount and low floor price.
• Risk of incurring substantial liquidated damages if the company fails to timely register the conversion shares, maintain public information, or effect a mandatory reverse stock split.
• The requirement for a reverse stock split if the common stock price falls below $0.0681 indicates potential challenges in maintaining exchange listing and could negatively impact investor perception and liquidity.
• The company's ability to generate sufficient cash flow from operations to avoid further dilutive financing or to cover potential liquidated damages.

Future Outlook

The company plans to use the net proceeds from the offering for marketing and working capital. It is obligated to file an initial registration statement to allow for the resale of the common stock issuable upon conversion of the Series C Preferred Stock. Furthermore, the company must monitor its common stock price and may be required to effect a reverse stock split if the price falls below the specified Floor Price of $0.0681 for five consecutive trading days, to maintain exchange listing compliance.

Management Comments

• Katharyn Field, Chief Executive Officer, signed the filing on behalf of iSpecimen Inc.

Industry Context

This capital raise through convertible preferred stock is a common strategy for life sciences and biotechnology companies like iSpecimen Inc., which often require significant funding for research, development, and operational expenses. The terms of the offering, including a conversion discount and a low floor price, suggest the company may be in a growth phase requiring substantial capital or facing challenges in securing less dilutive forms of financing. The provisions for a mandatory reverse stock split are typical for companies whose share price is at risk of falling below exchange listing requirements, a common issue in the volatile biotech sector.

Comparison to Industry Standards

• The issuance of convertible preferred stock with a conversion discount (85% of closing price) and a low floor price ($0.0681) is often observed in early-stage or financially challenged companies within the biotech and life sciences sectors, where traditional equity financing might be difficult to secure at higher valuations.
• Placement agent fees of 5% (4% cash + 1% expense allowance) are within the typical range for private placements, particularly for smaller public companies or those with higher perceived risk, compared to larger, more established firms that might command lower fees.
• The inclusion of robust liquidated damages clauses for failures in registration, public information, and reverse stock splits is standard practice in such agreements, reflecting the investors' need for protection against company non-compliance and potential loss of liquidity.
• The 180-day lock-up period for officers, directors, and significant shareholders is a customary measure to demonstrate commitment and stability following a capital raise, aligning with industry norms for public offerings and private placements.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Face significant potential dilution due to the conversion terms of the Series C Preferred Stock (85% discount, low floor price). The mandatory reverse stock split could also negatively impact perception and liquidity.
• Investors (Series C Preferred Stock): Benefit from a 20% discount on purchase price, senior ranking in liquidation, and a conversion mechanism designed to protect their investment, including a floor price. They are also protected by substantial liquidated damages clauses for company non-compliance.
• Employees: The capital raise provides working capital, which can support ongoing operations and employment, but the underlying financial challenges and dilutive terms may signal future instability.
• Creditors: The capital raise improves the company's immediate cash position, which is positive. However, the senior ranking of Series C Preferred Stock in liquidation means these investors would be paid before common shareholders, but after existing creditors.

Next Steps

• The company is required to file an initial registration statement to register the common stock issuable upon conversion of the Series C Preferred Stock for resale.
• The company must maintain a reserve of common stock equal to five times the number of shares issuable upon full conversion of all outstanding Series C at the Floor Price.
• Officers, directors, and 5%+ shareholders are subject to a 180-day lock-up period following the closing of the offering.
• The company must monitor its common stock price and initiate a reverse stock split if the lowest closing price falls below $0.0681 for five consecutive trading days.

Key Dates

Recommendation

The terms of this private placement, including the significant discount on the preferred stock, the low conversion floor price, and the stringent liquidated damages clauses, suggest the company is in a precarious financial position. The mandatory reverse stock split provision further indicates concerns about maintaining exchange listing and potential for further share price erosion. While the capital raise provides immediate liquidity, the long-term implications for common shareholders, particularly dilution and the unfavorable terms, are substantial. Investors should consider exiting their positions to avoid further downside risk.

Keywords

iSpecimen Inc., ISPC, Series C Preferred Stock, Convertible Preferred Stock, Private Placement, Capital Raise, Securities Purchase Agreement, Registration Rights, E.F. Hutton, Dilution, Corporate Finance, Nasdaq, Reverse Stock Split